Sign In
Free Newsletter
Citius Pharma finalizes $675M oncology unit spinoff
The newly combined public company with New York-headquartered TenX Keane Acquisition is now called Citius Oncology Inc.
Citius Pharma’s $675M merger deal advances (updated)
In 2022, the Cranford-based company announced its intentions to spin off its subsidiary to focus on a developing treatment for cutaneous T-cell lymphoma.
Citius Pharmaceuticals’ spinoff plans advance
The Cranford-based company enlisted Maxim Group LLC to serve as financial advisor to its wholly owned subsidiary, Citius Acquisition Corp. Inc., in connection with the move.
Citius Pharma to split into two companies
In preparation for the commercialization of its two late-stage products, the biopharmaceutical firm plans to form NewCo to focus on developing and commercializing its treatment for cutaneous T-cell lymphoma.
NJBIZ Conversations: Leonard Mazur
Citius Pharmaceuticals Executive Chairman Leonard Mazur discusses the company's pipeline and the business climate for the industry in the state.
Citius Pharma restructures management team
The Cranford company's co-founders will transition to new roles before the anticipated launches of its first commercial products.
Citius Pharma names EVP of chemistry, manufacturing, controls
Kelly Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Cranford-based company's five pipeline programs.
